- Home
- IMPP vs SLS Comparison
IMPP vs SLS Comparison
Compare IMPP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- SLS
- Stock Information
- Founded
- IMPP 1981
- SLS 2012
- Country
- IMPP Greece
- SLS United States
- Employees
- IMPP N/A
- SLS N/A
- Industry
- IMPP Marine Transportation
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- SLS Health Care
- Exchange
- IMPP Nasdaq
- SLS Nasdaq
- Market Cap
- IMPP 99.2M
- SLS 89.6M
- IPO Year
- IMPP N/A
- SLS N/A
- Fundamental
- Price
- IMPP $2.44
- SLS $1.09
- Analyst Decision
- IMPP
- SLS
- Analyst Count
- IMPP 0
- SLS 0
- Target Price
- IMPP N/A
- SLS N/A
- AVG Volume (30 Days)
- IMPP 127.4K
- SLS 811.7K
- Earning Date
- IMPP 05-15-2025
- SLS 05-13-2025
- Dividend Yield
- IMPP N/A
- SLS N/A
- EPS Growth
- IMPP N/A
- SLS N/A
- EPS
- IMPP 1.40
- SLS N/A
- Revenue
- IMPP $147,479,980.00
- SLS N/A
- Revenue This Year
- IMPP $3.05
- SLS N/A
- Revenue Next Year
- IMPP $47.92
- SLS N/A
- P/E Ratio
- IMPP $1.75
- SLS N/A
- Revenue Growth
- IMPP N/A
- SLS N/A
- 52 Week Low
- IMPP $2.23
- SLS $0.77
- 52 Week High
- IMPP $4.59
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- IMPP 39.85
- SLS 40.56
- Support Level
- IMPP $2.35
- SLS $1.13
- Resistance Level
- IMPP $2.60
- SLS $1.25
- Average True Range (ATR)
- IMPP 0.08
- SLS 0.07
- MACD
- IMPP 0.01
- SLS -0.01
- Stochastic Oscillator
- IMPP 36.00
- SLS 17.39
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.